Cel Sci (CVM) EBT (QoQ) (2010 - 2026)
Cel Sci (CVM) EBT (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Cel Sci | 2.16 Mn | -4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134.11% |
| Dec 31, 2025 | 30.18% |
| Sep 30, 2025 | 47.93% |
| Jun 30, 2025 | -131.58% |
| Mar 31, 2025 | 7.45% |
| Dec 31, 2024 | -15.28% |
| Sep 30, 2024 | 67.79% |
| Jun 30, 2024 | 5.31% |
| Mar 31, 2024 | 0.22% |
| Dec 31, 2023 | -150.50% |
| Sep 30, 2023 | 65.23% |
| Jun 30, 2023 | 2.68% |
| Mar 31, 2023 | -200.42% |
| Dec 31, 2022 | 24.11% |
| Sep 30, 2022 | 60.22% |
| Jun 30, 2022 | 5.11% |
| Mar 31, 2022 | -203.91% |
| Dec 31, 2021 | -6.23% |
| Sep 30, 2021 | 18.00% |
| Jun 30, 2021 | 7.06% |